Evidence map›Paper›PMID 36912204›Full record

ArticleJournal of the International AIDS Society2023

Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya.

Mercelline Ogolla, Omoto Lennah Nyabiage, Paul Musingila, Susan Gachau, Theresa M A Odero, Elijah Odoyo-June, Boniface Ochanda, Aoko Appolonia, Elizabeth Katiku, Rachael Joseph and 4 more

Full text read
In one paragraph

Article in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Retention of clients in HIV oral pre-exposure prophylaxis care in Engela, Namibia.African journal of primary health care & family medicine · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Brief Report: HIV Pre-Exposure Prophylaxis Awareness and Use Among Adolescents in Kenya.Journal of acquired immune deficiency syndromes (1999) · 2024
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mercelline OgollaAfya Bora Consortium, Department of Global Health, University of Washington, Seattle, Washington, USA.
Omoto Lennah NyabiageDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Paul MusingilaDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Susan GachauDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Theresa M A OderoAfya Bora Consortium, Department of Global Health, University of Washington, Seattle, Washington, USA.
Elijah Odoyo-JuneDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Boniface OchandaDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Aoko AppoloniaDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Elizabeth KatikuDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Rachael JosephDivision of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
Cirrilus OgollaCenter for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Linda OtienoCenter for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Francesca OdhiamboCenter for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Hong-Ha M TruongDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
CGH CDC HHS NU2GGH001947NIMH NIH HHS P30 MH062246PEPFAR
6 · The paper itself

Abstract

introductionIn 2020, Kenya had 19,000 new HIV infections among women aged 15+ years. Studies have shown sub-optimal oral pre-exposure prophylaxis (PrEP) use among sub-populations of women. We assessed the uptake and continuation of oral PrEP among women 15-49 years in two health facilities in Kisumu County, Kenya.

methodsA retrospective cohort of 262 women aged 15-49 years, initiated into oral PrEP between 12 November 2019 and 31 March 2021, was identified from two health facilities in the urban setting of Kisumu County, Kenya. Data on baseline characteristics and oral PrEP continuation at months 1, 3 and 6 were abstracted from patient records and summarized using descriptive statistics. Missing data in the predictor variables were imputed within the joint modelling multiple imputation framework. Using logistic regression, we evaluated factors associated with the discontinuation of oral PrEP at month 1.

resultsOf the 66,054 women screened, 320 (0.5%) were eligible and 262 (82%) were initiated on oral PrEP. Uptake was higher among women 25-29 years as compared to those 15-24 years (77% vs. 33%). Oral PrEP continuation declined significantly with increasing duration of follow-up; 37% at month 1, 21% at month 3 and 12% at month 6 (p<0.05). In the adjusted analysis, women 15-24 years had lower adjusted odds of continuing at month 1 than women ≥25 years (adjusted odds ratio [aOR]: 0.41, 95% CI: 0.21-0.82). There was no association between being sero-discordant and continuation of oral PrEP at month 1 (aOR; 1.21, 95% CI 0.59-2.50). Women from the sub-county hospital were more likely to continue at month 1 of follow-up compared to women enrolled in the county referral hospital (aOR 5.11; 95% CI 2.24-11.70).

conclusionsThe low eligibility for oral PrEP observed among women 15-49 years in an urban setting with high HIV prevalence calls for a review of the screening process to validate the sensitivity of the screening tool and its proper application. The low uptake and continuation among adolescent girls and young women underscores the need to identify and address specific patient- and facility-level barriers affecting different sub-populations at risk for HIV acquisition.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentAdultFemaleHealth FacilitiesHumansKenyaMiddle AgedRetrospective StudiesYoung AdultAnti-HIV Agentsadolescent girls and young womencontinuationHIV preventionoral pre-exposure prophylaxisuptakewomen of reproductive age

Identifiers

PMID36912204
PMCPMC10009800

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read180
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.